PharmaShots | Incisive News in 3 Shots

Subscribe Now

incyte

Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024

Incyte Highlights the P-III (inMIND) Study Data of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024

December 11, 2024

Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab-csfr) to Treat Chronic Graft-Versus-Host Disease (GvHD)

Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab-csfr) to Treat Chronic Graft-Versus-Host Disease (GvHD)

August 16, 2024

$Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL$

Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL

August 16, 2024

Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

April 24, 2024

Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications

Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Derma...

April 2, 2024

Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24

Incyte Highlights Results from the P-II Trial of Povorcitinib for the Treatment of Prurigo Nodularis at AAD’24

March 11, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us